PAA

8.89%

20.5¢ pharmaust limited

Ann: Second Cancer Patient Completes Course With Stable Disease, page-35

First 35 Last

Share
Profile

Follow
Banastas

451 Posts.

85

05/03/15

20:00

Post #: 14867716
Share

Originally posted by fever2tell ↑

Biotech Daily
Thursday March 5, 2015

Pharmaust says the second patient in its trial of PPL-1 for cancer has completed the 28-
day treatment at the lowest dose without material adverse events and with stable disease.
Pharmaust said that the Royal Adelaide Hospital patient had bowel cancer and the drug
was “well-tolerated, without material adverse events and the patient ... had stable disease
on completion of the treatment” as determined by computed tomography scan.
The company said that subject to the third patient in the low-dose group completing the
treatment schedule by mid-March, the trial would move to higher doses.
Pharmaust said that in parallel to monitoring patients who had completed the full 28-day
trial period, it was monitoring levels of the biomarker P70S6K in all patients who received
PPL-1 and had stayed on therapy for at least three days.
The company said that a number of patients had to be withdrawn due to reasons
unrelated to the study drug.
Pharmaust said that PPL-1 appeared to define “a new and unexpected mechanism of
action representing a potentially new class of anti-cancer drug”.
The company said that PPL-1 influenced the mammalian target of rapamycin (mTOR)
pathway, but, unlike other mTOR drugs, like Novartis’ Afinitor, or everolimus, and Pfizer’s
Sirolimus or rapamycin, it appeared to have very low toxicity.
Pharmaust said that PPL-1 had not shown an adverse event profile commonly associated
with conventional anti-cancer drugs, the lowest dose of PPL-1 had shown meaningful
reductions in the cancer marker P70S6K and PPL-1 targetted a biochemical pathway that
affected a range of regulatory mediators, without the side effect profile of other mTOR
drugs currently on the market.
Pharmaust was unchanged at 0.8 cents with 4.8 million shares traded.

Expand

Thanks for posting

PAA Price at posting: 0.8¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

RDN

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

SBW

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

STX

Strike Energy secures $153 million for Perth Basin gas projects

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

BRX

Belararox delineates another porphyry in Argentina at Tambo South

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

GYG

Guzman Y Gomez shot up nearly 40% in first hour of trades. Can it last?

FHE

Frontier Energy achieves key milestone for Waroona energy project

AML

Cultural heritage agreement puts Walford Creek exploration back on the map

First 35 Last

Add PAA (ASX) to my watchlist

(20min delay)
Last 20.5¢		Change -0.020(8.89%)		Mkt cap ! $81.16M

Open	High	Low	Value	Volume
20.0¢	21.0¢	19.5¢	$331.9K	1.617M

Buyers (Bids)

No.	Vol.	Price($)
4	440882	20.5¢

Sellers (Offers)

Price($)	Vol.	No.
21.0¢	12736	3

View Market Depth

No.	Vol.	Price($)
4	440882	0.205
9	278609	0.200
9	134197	0.195
16	349570	0.190
6	478648	0.185

Price($)	Vol.	No.
0.210	12736	3
0.215	120000	1
0.235	25000	1
0.240	60977	5
0.245	41137	3

Last trade - 16.10pm 21/06/2024 (20 minute delay)

PAA (ASX) Chart

Ann: Second Cancer Patient Completes Course With Stable Disease, page-35

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Strike Energy secures $153 million for Perth Basin gas projects

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Belararox delineates another porphyry in Argentina at Tambo South

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Guzman Y Gomez shot up nearly 40% in first hour of trades. Can it last?

Frontier Energy achieves key milestone for Waroona energy project

Cultural heritage agreement puts Walford Creek exploration back on the map

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Second Cancer Patient Completes Course With Stable Disease, page-35

Top Stories

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Strike Energy secures $153 million for Perth Basin gas projects

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Belararox delineates another porphyry in Argentina at Tambo South

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Guzman Y Gomez shot up nearly 40% in first hour of trades. Can it last?

Frontier Energy achieves key milestone for Waroona energy project

Cultural heritage agreement puts Walford Creek exploration back on the map

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News